Global Encephalitis Vaccines Market By Type (Inactivated mouse brain-derived vaccines, Inactivated vero cell-derived vaccines, Live attenuated vaccines, Live recombinant (chimeric) vaccines); By Demography (Children, Adults); By Mode of Administration (Oral, Intramuscular, Subcutaneous); By End User (Hospitals, Specialty Clinics, Research Institutes); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031
Industry Trends
The global encephalitis vaccines market is growing at a CAGR of 19.5% over the forecast period (2023 – 2031).
Encephalitis vaccines are a type of vaccine used to protect against encephalitis, a condition that causes inflammation of the brain and can be potentially fatal. Encephalitis is caused by various viruses including herpes simplex, varicella zoster, West Nile virus, Japanese encephalitis virus and St. Louis encephalitis virus. Vaccines provide protection from these viruses by stimulating the body’s immune system to produce antibodies which recognize and then fight the virus. The vaccines can be administered via intramuscular injection or in combination with other vaccines such as those for measles, mumps and rubella (MMR). These vaccines are recommended for people who live in areas where the risk of infection is high or for travellers planning to visit such areas, which is driving the demand of encephalitis vaccines market. The encephalitis vaccine is particularly important for children under the age of 15 years old as they are most susceptible to this type of infection due to their immature immune systems. Some countries such as India offer free vaccinations for children up to the age of 18 months through their Universal Immunization Program (UIP). In addition, parents should ensure that their child receives any recommended vaccinations before traveling abroad in order to minimize the risk of infection.
Global Encephalitis Vaccines Market Revenue & Forecast, (US$ Million), 2015 – 2031
Encephalitis vaccines are typically administered via injection, either intramuscular or subcutaneous. Generally, two doses of the vaccine are given at least four weeks apart for full protection against the viruses which may cause encephalitis. In some cases, a booster dose may be recommended after a few years. Vaccinations may also be administered orally in certain cases, such as when the patient is unable to tolerate an injection.
In North America, the United States has taken a lead in terms of encephalitis vaccinations. The Centers for Disease Control and Prevention (CDC) recommends that all people aged 6 months or older receive two doses of vaccination to protect against encephalitis caused by certain viruses like mumps, measles, rubella and varicella-zoster virus (the virus responsible for chickenpox). Additionally, some states such as California mandate the MMR-V vaccine which combines protection against four different viruses in one injection. Approximately 1 in 4 people in the United States are at a risk of acquiring an encephalitis caused by one of several viruses such as mumps, measles, rubella and varicella-zoster virus (the virus responsible for chickenpox). This means that individual states have varied rates of infection, with some having higher overall rates than others. Vaccines are an important tool in preventing the spread of encephalitis, and since 2000 there has been a significant decrease in reported cases due to improvements in vaccination coverage. However, there is still work to be done; research indicates that immunisation coverage varies by state and could still be improved to better protect vulnerable populations from certain infectious diseases, which in turn id driving the demand of encephalitis vaccines market across North America.
Competitive Landscape
The report provides both, qualitative and quantitative research of global encephalitis vaccines market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the key market participants operating in the global encephalitis vaccines market are
- Bharat Biotech
- Biological E. Ltd
- Intercell
- KM Biologics
- Medigen, Inc.
- Pfizer Inc
- Sanofi
- Valneva USA Inc
- Other Industry Participants
Global Encephalitis Vaccines Market
By Type
- Inactivated mouse brain-derived vaccines
- Inactivated vero cell-derived vaccines
- Live attenuated vaccines
- Live recombinant (chimeric) vaccines
By Demography
- Children
- Adults
By Mode of Administration
- Oral
- Intramuscular
- Subcutaneous
By End User
- Hospitals
- Specialty Clinics
- Research Institutes
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1.
Market
Scope
1.1.
Market
Segmentation
1.2.
Years
Considered
1.2.1.
Historic
Years: 2015 - 2021
1.2.2.
Base
Year: 2022
1.2.3.
Forecast
Years: 2023 – 2031
2.
Key
Target Audiences
3.
Research
Methodology
3.1.
Primary
Research
3.1.1.
Research
Questionnaire
3.1.2.
Global
Percentage Breakdown
3.1.3.
Primary
Interviews: Key Opinion Leaders (KOLs)
3.2.
Secondary
Research
3.2.1.
Paid
Databases
3.2.2.
Secondary
Sources
3.3.
Market
Size Estimates
3.3.1.
Top-Down
Approach
3.3.2.
Bottom-Up
Approach
3.4.
Data
Triangulation Methodology
3.5.
Research
Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Encephalitis Vaccines Market
6.
Market
Synopsis: Encephalitis Vaccines Market
7.
Encephalitis
Vaccines Market Analysis: Qualitative Perspective
7.1.
Introduction
7.1.1.
Product
Definition
7.1.2.
Industry
Development
7.2.
Market
Dynamics
7.2.1.
Drivers
7.2.2.
Restraints
7.2.3.
Opportunities
7.2.4.
Challenges
7.3.
Trends
in Encephalitis Vaccines Market
7.4.
Market
Determinants Radar Chart
7.5.
Macro-Economic
and Micro-Economic Indicators: Encephalitis Vaccines Market
7.6.
Porter’s
Five Force Analysis
7.7.
Impact
of Covid-19 on Encephalitis Vaccines Market
8.
Global Encephalitis
Vaccines Market Analysis and Forecasts, 2023 – 2031
8.1.
Overview
8.1.1.
Global Encephalitis
Vaccines Market Revenue (US$ Mn)
8.2.
Global Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1.
Inactivated
mouse brain-derived vaccines
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.1.3.
Market
Forecast, 2023 – 2031
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2022
8.2.1.5.1.2. Market Forecast, 2023 – 2031
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2022
8.2.1.5.2.2. Market Forecast, 2023 – 2031
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2022
8.2.1.5.3.2. Market Forecast, 2023 – 2031
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2022
8.2.1.5.4.2. Market Forecast, 2023 – 2031
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2022
8.2.1.5.5.2. Market Forecast, 2023 – 2031
8.2.2.
Inactivated
vero cell-derived vaccines
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.2.3.
Market
Forecast, 2023 – 2031
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2022
8.2.2.5.1.2. Market Forecast, 2023 – 2031
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2022
8.2.2.5.2.2. Market Forecast, 2023 – 2031
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2022
8.2.2.5.3.2. Market Forecast, 2023 – 2031
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2022
8.2.2.5.4.2. Market Forecast, 2023 – 2031
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2022
8.2.2.5.5.2. Market Forecast, 2023 – 2031
8.2.3.
Live
attenuated vaccines
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.3.3.
Market
Forecast, 2023 – 2031
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2022
8.2.3.5.1.2. Market Forecast, 2023 – 2031
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2022
8.2.3.5.2.2. Market Forecast, 2023 – 2031
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2022
8.2.3.5.3.2. Market Forecast, 2023 – 2031
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2022
8.2.3.5.4.2. Market Forecast, 2023 – 2031
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2022
8.2.3.5.5.2. Market Forecast, 2023 – 2031
8.2.4.
Live
recombinant (chimeric) vaccines
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.4.3.
Market
Forecast, 2023 – 2031
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2022
8.2.4.5.1.2. Market Forecast, 2023 – 2031
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2022
8.2.4.5.2.2. Market Forecast, 2023 – 2031
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2022
8.2.4.5.3.2. Market Forecast, 2023 – 2031
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2022
8.2.4.5.4.2. Market Forecast, 2023 – 2031
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2022
8.2.4.5.5.2. Market Forecast, 2023 – 2031
8.3.
Key
Segment for Channeling Investments
8.3.1.
By Type
9.
Global Encephalitis
Vaccines Market Analysis and Forecasts, 2023 – 2031
9.1.
Overview
9.2.
Global Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
9.2.1.
Children
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.1.3.
Market
Forecast, 2023 – 2031
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2022
9.2.1.5.1.2. Market Forecast, 2023 – 2031
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2022
9.2.1.5.2.2. Market Forecast, 2023 – 2031
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2022
9.2.1.5.3.2. Market Forecast, 2023 – 2031
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2022
9.2.1.5.4.2. Market Forecast, 2023 – 2031
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2022
9.2.1.5.5.2. Market Forecast, 2023 – 2031
9.2.2.
Adults
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.2.3.
Market
Forecast, 2023 – 2031
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2022
9.2.2.5.1.2. Market Forecast, 2023 – 2031
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2022
9.2.2.5.2.2. Market Forecast, 2023 – 2031
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2022
9.2.2.5.3.2. Market Forecast, 2023 – 2031
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2022
9.2.2.5.4.2. Market Forecast, 2023 – 2031
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2022
9.2.2.5.5.2. Market Forecast, 2023 – 2031
9.3.
Key
Segment for Channeling Investments
9.3.1.
By
Demography
10. Global Encephalitis Vaccines Market Analysis
and Forecasts, 2023 – 2031
10.1. Overview
10.2. Global Encephalitis Vaccines Market Revenue
(US$ Mn) and Forecasts, By Mode of Administration
10.2.1. Oral
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.1.3.
Market
Forecast, 2023 – 2031
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2022
10.2.1.5.1.2. Market Forecast, 2023 – 2031
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2022
10.2.1.5.2.2. Market Forecast, 2023 – 2031
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2022
10.2.1.5.3.2. Market Forecast, 2023 – 2031
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2022
10.2.1.5.4.2. Market Forecast, 2023 – 2031
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2022
10.2.1.5.5.2. Market Forecast, 2023 – 2031
10.2.2. Intramuscular
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.2.3.
Market
Forecast, 2023 – 2031
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2022
10.2.2.5.1.2. Market Forecast, 2023 – 2031
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2022
10.2.2.5.2.2. Market Forecast, 2023 – 2031
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2022
10.2.2.5.3.2. Market Forecast, 2023 – 2031
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2022
10.2.2.5.4.2. Market Forecast, 2023 – 2031
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2022
10.2.2.5.5.2. Market Forecast, 2023 – 2031
10.2.3. Subcutaneous
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2022
10.2.3.3.
Market
Forecast, 2023 – 2031
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1.
North
America
10.2.3.5.1.1. Market Estimation, 2015 - 2022
10.2.3.5.1.2. Market Forecast, 2023 – 2031
10.2.3.5.2.
Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2022
10.2.3.5.2.2. Market Forecast, 2023 – 2031
10.2.3.5.3.
Asia
Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2022
10.2.3.5.3.2. Market Forecast, 2023 – 2031
10.2.3.5.4.
Middle
East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2022
10.2.3.5.4.2. Market Forecast, 2023 – 2031
10.2.3.5.5.
Latin
America
10.2.3.5.5.1. Market Estimation, 2015 - 2022
10.2.3.5.5.2. Market Forecast, 2023 – 2031
10.3. Key Segment for Channeling Investments
10.3.1. By Mode of Administration
11. Global Encephalitis Vaccines Market Analysis
and Forecasts, 2023 – 2031
11.1. Overview
11.2. Global Encephalitis Vaccines Market Revenue
(US$ Mn) and Forecasts, By End User
11.2.1. Hospitals
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
11.2.1.3.
Market
Forecast, 2023 – 2031
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2022
11.2.1.5.1.2. Market Forecast, 2023 – 2031
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2022
11.2.1.5.2.2. Market Forecast, 2023 – 2031
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2022
11.2.1.5.3.2. Market Forecast, 2023 – 2031
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2022
11.2.1.5.4.2. Market Forecast, 2023 – 2031
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2022
11.2.1.5.5.2. Market Forecast, 2023 – 2031
11.2.2. Specialty Clinics
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
11.2.2.3.
Market
Forecast, 2023 – 2031
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2022
11.2.2.5.1.2. Market Forecast, 2023 – 2031
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2022
11.2.2.5.2.2. Market Forecast, 2023 – 2031
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2022
11.2.2.5.3.2. Market Forecast, 2023 – 2031
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2022
11.2.2.5.4.2. Market Forecast, 2023 – 2031
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2022
11.2.2.5.5.2. Market Forecast, 2023 – 2031
11.2.3. Research Institutes
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2015 - 2022
11.2.3.3.
Market
Forecast, 2023 – 2031
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2015 - 2022
11.2.3.5.1.2. Market Forecast, 2023 – 2031
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2022
11.2.3.5.2.2. Market Forecast, 2023 – 2031
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2022
11.2.3.5.3.2. Market Forecast, 2023 – 2031
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2022
11.2.3.5.4.2. Market Forecast, 2023 – 2031
11.2.3.5.5.
Latin
America
11.2.3.5.5.1. Market Estimation, 2015 - 2022
11.2.3.5.5.2. Market Forecast, 2023 – 2031
11.3. Key Segment for Channeling Investments
11.3.1. By End User
12. North America Encephalitis Vaccines Market
Analysis and Forecasts, 2023 – 2031
12.1. Overview
12.1.1. North America Encephalitis Vaccines Market
Revenue (US$ Mn)
12.2. North America Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Inactivated mouse brain-derived vaccines
12.2.2. Inactivated vero cell-derived vaccines
12.2.3. Live attenuated vaccines
12.2.4. Live recombinant (chimeric) vaccines
12.3. North America Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Demography
12.3.1. Children
12.3.2. Adults
12.4. North America Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Mode of Administration
12.4.1. Oral
12.4.2. Intramuscular
12.4.3. Subcutaneous
12.5. North America Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By End User
12.5.1. Hospitals
12.5.2. Specialty Clinics
12.5.3. Research Institutes
12.6. North America Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1.
U.S Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
12.6.1.1.1.
Inactivated
mouse brain-derived vaccines
12.6.1.1.2.
Inactivated
vero cell-derived vaccines
12.6.1.1.3.
Live
attenuated vaccines
12.6.1.1.4.
Live
recombinant (chimeric) vaccines
12.6.1.2.
U.S Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
12.6.1.2.1.
Children
12.6.1.2.2.
Adults
12.6.1.3.
U.S Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
12.6.1.3.1.
Oral
12.6.1.3.2.
Intramuscular
12.6.1.3.3.
Subcutaneous
12.6.1.4.
U.S Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
12.6.1.4.1.
Hospitals
12.6.1.4.2.
Specialty
Clinics
12.6.1.4.3.
Research
Institutes
12.6.2. Canada
12.6.2.1.
Canada Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
12.6.2.1.1.
Inactivated
mouse brain-derived vaccines
12.6.2.1.2.
Inactivated
vero cell-derived vaccines
12.6.2.1.3.
Live attenuated
vaccines
12.6.2.1.4.
Live
recombinant (chimeric) vaccines
12.6.2.2.
Canada Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
12.6.2.2.1.
Children
12.6.2.2.2.
Adults
12.6.2.3.
Canada Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
12.6.2.3.1.
Oral
12.6.2.3.2.
Intramuscular
12.6.2.3.3.
Subcutaneous
12.6.2.4.
Canada Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
12.6.2.4.1.
Hospitals
12.6.2.4.2.
Specialty
Clinics
12.6.2.4.3.
Research
Institutes
12.6.3. Mexico
12.6.3.1.
Mexico Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
12.6.3.1.1.
Inactivated
mouse brain-derived vaccines
12.6.3.1.2.
Inactivated
vero cell-derived vaccines
12.6.3.1.3.
Live
attenuated vaccines
12.6.3.1.4.
Live
recombinant (chimeric) vaccines
12.6.3.2.
Mexico Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
12.6.3.2.1.
Children
12.6.3.2.2.
Adults
12.6.3.3.
Mexico Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
12.6.3.3.1.
Oral
12.6.3.3.2.
Intramuscular
12.6.3.3.3.
Subcutaneous
12.6.3.4.
Mexico Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
12.6.3.4.1.
Hospitals
12.6.3.4.2.
Specialty
Clinics
12.6.3.4.3.
Research
Institutes
12.6.4. Rest of North America
12.6.4.1.
Rest of
North America Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Type
12.6.4.1.1.
Inactivated
mouse brain-derived vaccines
12.6.4.1.2.
Inactivated
vero cell-derived vaccines
12.6.4.1.3.
Live
attenuated vaccines
12.6.4.1.4.
Live
recombinant (chimeric) vaccines
12.6.4.2.
Rest of
North America Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Demography
12.6.4.2.1.
Children
12.6.4.2.2.
Adults
12.6.4.3.
Rest of
North America Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
12.6.4.3.1.
Oral
12.6.4.3.2.
Intramuscular
12.6.4.3.3.
Subcutaneous
12.6.4.4.
Rest of
North America Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
End User
12.6.4.4.1.
Hospitals
12.6.4.4.2.
Specialty
Clinics
12.6.4.4.3.
Research
Institutes
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Type
12.7.3. By Demography
12.7.4. By Mode of Administration
12.7.5. By End User
13. Europe Encephalitis Vaccines Market Analysis
and Forecasts, 2023 – 2031
13.1. Overview
13.1.1. Europe Encephalitis Vaccines Market Revenue
(US$ Mn)
13.2. Europe Encephalitis Vaccines Market Revenue
(US$ Mn) and Forecasts, By Type
13.2.1. Inactivated mouse brain-derived vaccines
13.2.2. Inactivated vero cell-derived vaccines
13.2.3. Live attenuated vaccines
13.2.4. Live recombinant (chimeric) vaccines
13.3. Europe Encephalitis Vaccines Market Revenue
(US$ Mn) and Forecasts, By Demography
13.3.1. Children
13.3.2. Adults
13.4. Europe Encephalitis Vaccines Market Revenue
(US$ Mn) and Forecasts, By Mode of Administration
13.4.1. Oral
13.4.2. Intramuscular
13.4.3. Subcutaneous
13.5. Europe Encephalitis Vaccines Market Revenue
(US$ Mn) and Forecasts, By End User
13.5.1. Hospitals
13.5.2. Specialty Clinics
13.5.3. Research Institutes
13.6. Europe Encephalitis Vaccines Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1.
France Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
13.6.1.1.1.
Inactivated
mouse brain-derived vaccines
13.6.1.1.2.
Inactivated
vero cell-derived vaccines
13.6.1.1.3.
Live
attenuated vaccines
13.6.1.1.4.
Live
recombinant (chimeric) vaccines
13.6.1.2.
France Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
13.6.1.2.1.
Children
13.6.1.2.2.
Adults
13.6.1.3.
France Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
13.6.1.3.1.
Oral
13.6.1.3.2.
Intramuscular
13.6.1.3.3.
Subcutaneous
13.6.1.4.
France Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
13.6.1.4.1.
Hospitals
13.6.1.4.2.
Specialty
Clinics
13.6.1.4.3.
Research
Institutes
13.6.2. The UK
13.6.2.1.
The UK Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
13.6.2.1.1.
Inactivated
mouse brain-derived vaccines
13.6.2.1.2.
Inactivated
vero cell-derived vaccines
13.6.2.1.3.
Live
attenuated vaccines
13.6.2.1.4.
Live
recombinant (chimeric) vaccines
13.6.2.2.
The UK Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
13.6.2.2.1.
Children
13.6.2.2.2.
Adults
13.6.2.3.
The UK Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
13.6.2.3.1.
Oral
13.6.2.3.2.
Intramuscular
13.6.2.3.3.
Subcutaneous
13.6.2.4.
The UK Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
13.6.2.4.1.
Hospitals
13.6.2.4.2.
Specialty
Clinics
13.6.2.4.3.
Research
Institutes
13.6.3. Spain
13.6.3.1.
Spain Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
13.6.3.1.1.
Inactivated
mouse brain-derived vaccines
13.6.3.1.2.
Inactivated
vero cell-derived vaccines
13.6.3.1.3.
Live
attenuated vaccines
13.6.3.1.4.
Live
recombinant (chimeric) vaccines
13.6.3.2.
Spain Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
13.6.3.2.1.
Children
13.6.3.2.2.
Adults
13.6.3.3.
Spain Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
13.6.3.3.1.
Oral
13.6.3.3.2.
Intramuscular
13.6.3.3.3.
Subcutaneous
13.6.3.4.
Spain Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
13.6.3.4.1.
Hospitals
13.6.3.4.2.
Specialty
Clinics
13.6.3.4.3.
Research
Institutes
13.6.4. Germany
13.6.4.1.
Germany Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
13.6.4.1.1.
Inactivated
mouse brain-derived vaccines
13.6.4.1.2.
Inactivated
vero cell-derived vaccines
13.6.4.1.3.
Live
attenuated vaccines
13.6.4.1.4.
Live
recombinant (chimeric) vaccines
13.6.4.2.
Germany Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
13.6.4.2.1.
Children
13.6.4.2.2.
Adults
13.6.4.3.
Germany Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
13.6.4.3.1.
Oral
13.6.4.3.2.
Intramuscular
13.6.4.3.3.
Subcutaneous
13.6.4.4.
Germany Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
13.6.4.4.1.
Hospitals
13.6.4.4.2.
Specialty
Clinics
13.6.4.4.3.
Research
Institutes
13.6.5. Italy
13.6.5.1.
Italy Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
13.6.5.1.1.
Inactivated
mouse brain-derived vaccines
13.6.5.1.2.
Inactivated
vero cell-derived vaccines
13.6.5.1.3.
Live
attenuated vaccines
13.6.5.1.4.
Live
recombinant (chimeric) vaccines
13.6.5.2.
Italy Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
13.6.5.2.1.
Children
13.6.5.2.2.
Adults
13.6.5.3.
Italy Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
13.6.5.3.1.
Oral
13.6.5.3.2.
Intramuscular
13.6.5.3.3.
Subcutaneous
13.6.5.4.
Italy Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
13.6.5.4.1.
Hospitals
13.6.5.4.2.
Specialty
Clinics
13.6.5.4.3.
Research
Institutes
13.6.6. Nordic Countries
13.6.6.1.
Nordic
Countries Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
13.6.6.1.1.
Inactivated
mouse brain-derived vaccines
13.6.6.1.2.
Inactivated
vero cell-derived vaccines
13.6.6.1.3.
Live
attenuated vaccines
13.6.6.1.4.
Live
recombinant (chimeric) vaccines
13.6.6.2.
Nordic
Countries Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Demography
13.6.6.2.1.
Children
13.6.6.2.2.
Adults
13.6.6.3.
Nordic
Countries Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode
of Administration
13.6.6.3.1.
Oral
13.6.6.3.2.
Intramuscular
13.6.6.3.3.
Subcutaneous
13.6.6.4.
Nordic
Countries Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By End
User
13.6.6.4.1.
Hospitals
13.6.6.4.2.
Specialty
Clinics
13.6.6.4.3.
Research
Institutes
13.6.6.5.
Nordic
Countries Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux
Union Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
13.6.7.1.1.
Inactivated
mouse brain-derived vaccines
13.6.7.1.2.
Inactivated
vero cell-derived vaccines
13.6.7.1.3.
Live
attenuated vaccines
13.6.7.1.4.
Live
recombinant (chimeric) vaccines
13.6.7.2.
Benelux
Union Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Demography
13.6.7.2.1.
Children
13.6.7.2.2.
Adults
13.6.7.3.
Benelux
Union Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
13.6.7.3.1.
Oral
13.6.7.3.2.
Intramuscular
13.6.7.3.3.
Subcutaneous
13.6.7.4.
Benelux
Union Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
13.6.7.4.1.
Hospitals
13.6.7.4.2.
Specialty
Clinics
13.6.7.4.3.
Research
Institutes
13.6.7.5.
Benelux
Union Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The
Netherlands
13.6.7.5.3.
Luxembourg
13.6.8. Rest of Europe
13.6.8.1.
Rest of
Europe Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
13.6.8.1.1.
Inactivated
mouse brain-derived vaccines
13.6.8.1.2.
Inactivated
vero cell-derived vaccines
13.6.8.1.3.
Live
attenuated vaccines
13.6.8.1.4.
Live
recombinant (chimeric) vaccines
13.6.8.2.
Rest of
Europe Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Demography
13.6.8.2.1.
Children
13.6.8.2.2.
Adults
13.6.8.3.
Rest of
Europe Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
13.6.8.3.1.
Oral
13.6.8.3.2.
Intramuscular
13.6.8.3.3.
Subcutaneous
13.6.8.4.
Rest of
Europe Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
13.6.8.4.1.
Hospitals
13.6.8.4.2.
Specialty
Clinics
13.6.8.4.3.
Research
Institutes
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Type
13.7.3. By Demography
13.7.4. By Mode of Administration
13.7.5. By End User
14. Asia Pacific Encephalitis Vaccines Market
Analysis and Forecasts, 2023 – 2031
14.1. Overview
14.1.1. Asia Pacific Encephalitis Vaccines Market
Revenue (US$ Mn)
14.2. Asia Pacific Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Inactivated mouse brain-derived vaccines
14.2.2. Inactivated vero cell-derived vaccines
14.2.3. Live attenuated vaccines
14.2.4. Live recombinant (chimeric) vaccines
14.3. Asia Pacific Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Demography
14.3.1. Children
14.3.2. Adults
14.4. Asia Pacific Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Mode of Administration
14.4.1. Oral
14.4.2. Intramuscular
14.4.3. Subcutaneous
14.5. Asia Pacific Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By End User
14.5.1. Hospitals
14.5.2. Specialty Clinics
14.5.3. Research Institutes
14.6. Asia Pacific Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1.
China Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
14.6.1.1.1.
Inactivated
mouse brain-derived vaccines
14.6.1.1.2.
Inactivated
vero cell-derived vaccines
14.6.1.1.3.
Live
attenuated vaccines
14.6.1.1.4.
Live
recombinant (chimeric) vaccines
14.6.1.2.
China Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
14.6.1.2.1.
Children
14.6.1.2.2.
Adults
14.6.1.3.
China Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
14.6.1.3.1.
Oral
14.6.1.3.2.
Intramuscular
14.6.1.3.3.
Subcutaneous
14.6.1.4.
China Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
14.6.1.4.1.
Hospitals
14.6.1.4.2.
Specialty
Clinics
14.6.1.4.3.
Research
Institutes
14.6.2. Japan
14.6.2.1.
Japan Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
14.6.2.1.1.
Inactivated
mouse brain-derived vaccines
14.6.2.1.2.
Inactivated
vero cell-derived vaccines
14.6.2.1.3.
Live
attenuated vaccines
14.6.2.1.4.
Live
recombinant (chimeric) vaccines
14.6.2.2.
Japan Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
14.6.2.2.1.
Children
14.6.2.2.2.
Adults
14.6.2.3.
Japan Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
14.6.2.3.1.
Oral
14.6.2.3.2.
Intramuscular
14.6.2.3.3.
Subcutaneous
14.6.2.4.
Japan Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
14.6.2.4.1.
Hospitals
14.6.2.4.2.
Specialty
Clinics
14.6.2.4.3.
Research
Institutes
14.6.3. India
14.6.3.1.
India Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
14.6.3.1.1.
Inactivated
mouse brain-derived vaccines
14.6.3.1.2.
Inactivated
vero cell-derived vaccines
14.6.3.1.3.
Live
attenuated vaccines
14.6.3.1.4.
Live
recombinant (chimeric) vaccines
14.6.3.2.
India Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
14.6.3.2.1.
Children
14.6.3.2.2.
Adults
14.6.3.3.
India Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
14.6.3.3.1.
Oral
14.6.3.3.2.
Intramuscular
14.6.3.3.3.
Subcutaneous
14.6.3.4.
India Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
14.6.3.4.1.
Hospitals
14.6.3.4.2.
Specialty
Clinics
14.6.3.4.3.
Research
Institutes
14.6.4. New Zealand
14.6.4.1.
New
Zealand Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
14.6.4.1.1.
Inactivated
mouse brain-derived vaccines
14.6.4.1.2.
Inactivated
vero cell-derived vaccines
14.6.4.1.3.
Live
attenuated vaccines
14.6.4.1.4.
Live
recombinant (chimeric) vaccines
14.6.4.2.
New
Zealand Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Demography
14.6.4.2.1.
Children
14.6.4.2.2.
Adults
14.6.4.3.
New
Zealand Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.6.4.3.1.
Oral
14.6.4.3.2.
Intramuscular
14.6.4.3.3.
Subcutaneous
14.6.4.4.
New
Zealand Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By End
User
14.6.4.4.1.
Hospitals
14.6.4.4.2.
Specialty
Clinics
14.6.4.4.3.
Research
Institutes
14.6.5. Australia
14.6.5.1.
Australia
Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
14.6.5.1.1.
Inactivated
mouse brain-derived vaccines
14.6.5.1.2.
Inactivated
vero cell-derived vaccines
14.6.5.1.3.
Live
attenuated vaccines
14.6.5.1.4.
Live
recombinant (chimeric) vaccines
14.6.5.2.
Australia
Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
14.6.5.2.1.
Children
14.6.5.2.2.
Adults
14.6.5.3.
Australia
Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.6.5.3.1.
Oral
14.6.5.3.2.
Intramuscular
14.6.5.3.3.
Subcutaneous
14.6.5.4.
Australia
Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
14.6.5.4.1.
Hospitals
14.6.5.4.2.
Specialty
Clinics
14.6.5.4.3.
Research
Institutes
14.6.6. South Korea
14.6.6.1.
South
Korea Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
14.6.6.1.1.
Inactivated
mouse brain-derived vaccines
14.6.6.1.2.
Inactivated
vero cell-derived vaccines
14.6.6.1.3.
Live
attenuated vaccines
14.6.6.1.4.
Live
recombinant (chimeric) vaccines
14.6.6.2.
South
Korea Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Demography
14.6.6.2.1.
Children
14.6.6.2.2.
Adults
14.6.6.3.
South
Korea Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.6.6.3.1.
Oral
14.6.6.3.2.
Intramuscular
14.6.6.3.3.
Subcutaneous
14.6.6.4.
South
Korea Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
14.6.6.4.1.
Hospitals
14.6.6.4.2.
Specialty
Clinics
14.6.6.4.3.
Research
Institutes
14.6.7. Southeast Asia
14.6.7.1.
Southeast
Asia Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
14.6.7.1.1.
Inactivated
mouse brain-derived vaccines
14.6.7.1.2.
Inactivated
vero cell-derived vaccines
14.6.7.1.3.
Live
attenuated vaccines
14.6.7.1.4.
Live
recombinant (chimeric) vaccines
14.6.7.2.
Southeast
Asia Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
14.6.7.2.1.
Children
14.6.7.2.2.
Adults
14.6.7.3.
Southeast
Asia Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
14.6.7.3.1.
Oral
14.6.7.3.2.
Intramuscular
14.6.7.3.3.
Subcutaneous
14.6.7.4.
Southeast
Asia Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
14.6.7.4.1.
Hospitals
14.6.7.4.2.
Specialty
Clinics
14.6.7.4.3.
Research
Institutes
14.6.7.5.
Southeast
Asia Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of
Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of
Asia Pacific Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Type
14.6.8.1.1.
Inactivated
mouse brain-derived vaccines
14.6.8.1.2.
Inactivated
vero cell-derived vaccines
14.6.8.1.3.
Live
attenuated vaccines
14.6.8.1.4.
Live
recombinant (chimeric) vaccines
14.6.8.2.
Rest of
Asia Pacific Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Demography
14.6.8.2.1.
Children
14.6.8.2.2.
Adults
14.6.8.3.
Rest of
Asia Pacific Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
14.6.8.3.1.
Oral
14.6.8.3.2.
Intramuscular
14.6.8.3.3.
Subcutaneous
14.6.8.4.
Rest of
Asia Pacific Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
End User
14.6.8.4.1.
Hospitals
14.6.8.4.2.
Specialty
Clinics
14.6.8.4.3.
Research
Institutes
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Type
14.7.3. By Demography
14.7.4. By Mode of Administration
14.7.5. By End User
15. Middle East and Africa Encephalitis Vaccines
Market Analysis and Forecasts, 2023 – 2031
15.1. Overview
15.1.1. Middle East and Africa Encephalitis Vaccines
Market Revenue (US$ Mn)
15.2. Middle East and Africa Encephalitis Vaccines
Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Inactivated mouse brain-derived vaccines
15.2.2. Inactivated vero cell-derived vaccines
15.2.3. Live attenuated vaccines
15.2.4. Live recombinant (chimeric) vaccines
15.3. Middle East and Africa Encephalitis Vaccines
Market Revenue (US$ Mn) and Forecasts, By Demography
15.3.1. Children
15.3.2. Adults
15.4. Middle East and Africa Encephalitis Vaccines
Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
15.4.1. Oral
15.4.2. Intramuscular
15.4.3. Subcutaneous
15.5. Middle East and Africa Encephalitis Vaccines
Market Revenue (US$ Mn) and Forecasts, By End User
15.5.1. Hospitals
15.5.2. Specialty Clinics
15.5.3. Research Institutes
15.6. Middle East and Africa Encephalitis Vaccines
Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi
Arabia Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.6.1.1.1.
Inactivated
mouse brain-derived vaccines
15.6.1.1.2.
Inactivated
vero cell-derived vaccines
15.6.1.1.3.
Live
attenuated vaccines
15.6.1.1.4.
Live
recombinant (chimeric) vaccines
15.6.1.2.
Saudi
Arabia Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Demography
15.6.1.2.1.
Children
15.6.1.2.2.
Adults
15.6.1.3.
Saudi
Arabia Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.6.1.3.1.
Oral
15.6.1.3.2.
Intramuscular
15.6.1.3.3.
Subcutaneous
15.6.1.4.
Saudi
Arabia Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
15.6.1.4.1.
Hospitals
15.6.1.4.2.
Specialty
Clinics
15.6.1.4.3.
Research
Institutes
15.6.2. UAE
15.6.2.1.
UAE Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.6.2.1.1.
Inactivated
mouse brain-derived vaccines
15.6.2.1.2.
Inactivated
vero cell-derived vaccines
15.6.2.1.3.
Live
attenuated vaccines
15.6.2.1.4.
Live
recombinant (chimeric) vaccines
15.6.2.2.
UAE Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
15.6.2.2.1.
Children
15.6.2.2.2.
Adults
15.6.2.3.
UAE Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
15.6.2.3.1.
Oral
15.6.2.3.2.
Intramuscular
15.6.2.3.3.
Subcutaneous
15.6.2.4.
UAE Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
15.6.2.4.1.
Hospitals
15.6.2.4.2.
Specialty
Clinics
15.6.2.4.3.
Research
Institutes
15.6.3. Egypt
15.6.3.1.
Egypt Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.6.3.1.1.
Inactivated
mouse brain-derived vaccines
15.6.3.1.2.
Inactivated
vero cell-derived vaccines
15.6.3.1.3.
Live
attenuated vaccines
15.6.3.1.4.
Live
recombinant (chimeric) vaccines
15.6.3.2.
Egypt Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
15.6.3.2.1.
Children
15.6.3.2.2.
Adults
15.6.3.3.
Egypt Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
15.6.3.3.1.
Oral
15.6.3.3.2.
Intramuscular
15.6.3.3.3.
Subcutaneous
15.6.3.4.
Egypt Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
15.6.3.4.1.
Hospitals
15.6.3.4.2.
Specialty
Clinics
15.6.3.4.3.
Research
Institutes
15.6.4. Kuwait
15.6.4.1.
Kuwait Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.6.4.1.1.
Inactivated
mouse brain-derived vaccines
15.6.4.1.2.
Inactivated
vero cell-derived vaccines
15.6.4.1.3.
Live
attenuated vaccines
15.6.4.1.4.
Live
recombinant (chimeric) vaccines
15.6.4.2.
Kuwait Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
15.6.4.2.1.
Children
15.6.4.2.2.
Adults
15.6.4.3.
Kuwait Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
15.6.4.3.1.
Oral
15.6.4.3.2.
Intramuscular
15.6.4.3.3.
Subcutaneous
15.6.4.4.
Kuwait Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
15.6.4.4.1.
Hospitals
15.6.4.4.2.
Specialty
Clinics
15.6.4.4.3.
Research
Institutes
15.6.5. South Africa
15.6.5.1.
South
Africa Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
15.6.5.1.1.
Inactivated
mouse brain-derived vaccines
15.6.5.1.2.
Inactivated
vero cell-derived vaccines
15.6.5.1.3.
Live
attenuated vaccines
15.6.5.1.4.
Live recombinant
(chimeric) vaccines
15.6.5.2.
South
Africa Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Demography
15.6.5.2.1.
Children
15.6.5.2.2.
Adults
15.6.5.3.
South
Africa Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
15.6.5.3.1.
Oral
15.6.5.3.2.
Intramuscular
15.6.5.3.3.
Subcutaneous
15.6.5.4.
South
Africa Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
15.6.5.4.1.
Hospitals
15.6.5.4.2.
Specialty
Clinics
15.6.5.4.3.
Research
Institutes
15.6.6. Rest of Middle East & Africa
15.6.6.1.
Rest of
Middle East & Africa Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts,
By Type
15.6.6.1.1.
Inactivated
mouse brain-derived vaccines
15.6.6.1.2.
Inactivated
vero cell-derived vaccines
15.6.6.1.3.
Live
attenuated vaccines
15.6.6.1.4.
Live
recombinant (chimeric) vaccines
15.6.6.2.
Rest of
Middle East & Africa Encephalitis Vaccines Market Revenue (US$ Mn) and
Forecasts, By Demography
15.6.6.2.1.
Children
15.6.6.2.2.
Adults
15.6.6.3.
Rest of
Middle East & Africa Encephalitis Vaccines Market Revenue (US$ Mn) and
Forecasts, By Mode of Administration
15.6.6.3.1.
Oral
15.6.6.3.2.
Intramuscular
15.6.6.3.3.
Subcutaneous
15.6.6.4.
Rest of
Middle East & Africa Encephalitis Vaccines Market Revenue (US$ Mn) and
Forecasts, By End User
15.6.6.4.1.
Hospitals
15.6.6.4.2.
Specialty
Clinics
15.6.6.4.3.
Research
Institutes
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Type
15.7.3. By Demography
15.7.4. By Mode of Administration
15.7.5. By End User
16. Latin America Encephalitis Vaccines Market
Analysis and Forecasts, 2023 – 2031
16.1. Overview
16.1.1. Latin America Encephalitis Vaccines Market
Revenue (US$ Mn)
16.2. Latin America Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Type
16.2.1. Inactivated mouse brain-derived vaccines
16.2.2. Inactivated vero cell-derived vaccines
16.2.3. Live attenuated vaccines
16.2.4. Live recombinant (chimeric) vaccines
16.3. Latin America Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Demography
16.3.1. Children
16.3.2. Adults
16.4. Latin America Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Mode of Administration
16.4.1. Oral
16.4.2. Intramuscular
16.4.3. Subcutaneous
16.5. Latin America Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By End User
16.5.1. Hospitals
16.5.2. Specialty Clinics
16.5.3. Research Institutes
16.6. Latin America Encephalitis Vaccines Market
Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1.
Brazil Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
16.6.1.1.1.
Inactivated
mouse brain-derived vaccines
16.6.1.1.2.
Inactivated
vero cell-derived vaccines
16.6.1.1.3.
Live
attenuated vaccines
16.6.1.1.4.
Live
recombinant (chimeric) vaccines
16.6.1.2.
Brazil Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
16.6.1.2.1.
Children
16.6.1.2.2.
Adults
16.6.1.3.
Brazil Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of Administration
16.6.1.3.1.
Oral
16.6.1.3.2.
Intramuscular
16.6.1.3.3.
Subcutaneous
16.6.1.4.
Brazil Encephalitis
Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
16.6.1.4.1.
Hospitals
16.6.1.4.2.
Specialty
Clinics
16.6.1.4.3.
Research
Institutes
16.6.2. Argentina
16.6.2.1.
Argentina
Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Type
16.6.2.1.1.
Inactivated
mouse brain-derived vaccines
16.6.2.1.2.
Inactivated
vero cell-derived vaccines
16.6.2.1.3.
Live
attenuated vaccines
16.6.2.1.4.
Live
recombinant (chimeric) vaccines
16.6.2.2.
Argentina
Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Demography
16.6.2.2.1.
Children
16.6.2.2.2.
Adults
16.6.2.3.
Argentina
Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By Mode of
Administration
16.6.2.3.1.
Oral
16.6.2.3.2.
Intramuscular
16.6.2.3.3.
Subcutaneous
16.6.2.4.
Argentina
Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By End User
16.6.2.4.1.
Hospitals
16.6.2.4.2.
Specialty
Clinics
16.6.2.4.3.
Research
Institutes
16.6.3. Rest of Latin America
16.6.3.1.
Rest of
Latin America Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Type
16.6.3.1.1.
Inactivated
mouse brain-derived vaccines
16.6.3.1.2.
Inactivated
vero cell-derived vaccines
16.6.3.1.3.
Live
attenuated vaccines
16.6.3.1.4.
Live
recombinant (chimeric) vaccines
16.6.3.2.
Rest of
Latin America Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Demography
16.6.3.2.1.
Children
16.6.3.2.2.
Adults
16.6.3.3.
Rest of
Latin America Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
Mode of Administration
16.6.3.3.1.
Oral
16.6.3.3.2.
Intramuscular
16.6.3.3.3.
Subcutaneous
16.6.3.4.
Rest of
Latin America Encephalitis Vaccines Market Revenue (US$ Mn) and Forecasts, By
End User
16.6.3.4.1.
Hospitals
16.6.3.4.2.
Specialty
Clinics
16.6.3.4.3.
Research
Institutes
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Type
16.7.3. By Demography
16.7.4. By Mode of Administration
16.7.5. By End User
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2022
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. Bharat Biotech
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Biological E. Ltd
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Intercell
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. KM Biologics
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Medigen, Inc.
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Pfizer Inc
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Sanofi
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Valneva USA Inc
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7.
Business
Strategies
18.9. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
